but was not affected by addition of ß1 integrin antibody (Fig. 6d). By contrast, a neutralizing antibody specific for VEGF receptor 2 (VEGFR2) did not affect lactadherin-induced AKT ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...

One of the most recent agents to enter phase 1 clinical trials, combretastatin A-4 phosphate (CA4P), represents a new class of antiangiogenic compounds that act by inducing apoptosis in target ...

Stay up to date on practice-changing data in community practice.

Cancer Res (2025) 85 (8_Supplement_1): 69.